Inverseon Focuses on Mucous and Smoking Cessation

SAN FRANCISCO, Jan. 12, 2012 — Inverseon, Inc., a pharmaceutical company developing drug therapies for the treatment of pulmonary disorders, announced that while it anticipates that its asthma program will advance with non-dilutive grants, it is focused on smoking cessation as the initial in…

INV102 Asthma Product Discussed at the European Respiratory Society

SAN FRANCISCO, Sept. 22, 2009 — A symposium was held last week at the European Respiratory Society’s annual meeting in Vienna, Austria entitled “Beta-blockers may now be beneficial in asthma and COPD.”
“It is remarkable how far Inverseon’s asthma program has a…

Inverseon’s Founder and SAB Member Published in PNAS

SAN FRANCISCO, Feb. 19, 2009 — Inverseon, Inc. (http://www.inverseon.com) announces the publication in the February 17, 2009 issue of the Proceedings of the National Academy of Sciences (PNAS) entitled, “Beta2-adrenoceptor signaling is required for the development of an asthma phen…

Inverseon’s Asthma Therapy Receives Notice of Allowance; Clinical Trial Highlighted in Lancet

SAN FRANCISCO, Jan. 14, 2009 — Inverseon, Inc. (http://www.inverseon.com) announces the receipt of a notice of allowance from the United States Patent Office covering its oral product INV102 for asthma. Additionally, a comment highlighting Inverseon’s clinical asthma study was publ…